Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19-Reference-Cited by-同舟云学术

Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19

Published:2021-08 Issue: Volume:69 Page:102035
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Fisk Marie,Althage Magnus^ORCID,Moosmang Sven,Greasley Peter J.,Cope Andrew P.,Jayne David RW.,Galloway James^ORCID,Hall Frances,Wilkinson Ian B.,Ambery Philip,Cheriyan Joseph^ORCID

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry (medical),Pulmonary and Respiratory Medicine

Reference125 articles.

1. Potential effects of coronaviruses on the cardiovascular system;Madjid;Jama Cardiol,2020

2. Lifting the mask on neurological manifestations of COVID-19;Pezzini;Nat. Rev. Neurol.,2020

3. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives;Nishiga;Nat. Rev. Cardiol.,2020

4. Extrapulmonary manifestations of COVID-19;Gupta;Nat. Med.,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?;Clinical Science;2024-06

2. COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines/SGLT2 prooxidant pathway;Journal of Thrombosis and Haemostasis;2024-01

3. Current and future strategies for targeting the endothelin pathway in cardiovascular disease;Nature Cardiovascular Research;2023-11-02

4. Coronavirus Disease 2019, Diabetes, and Inflammation: A Systemic Review;Metabolic Syndrome and Related Disorders;2023-05-01

5. Thymol regulates the Endothelin-1 at gene expression and protein synthesis levels in septic rats;Chemico-Biological Interactions;2023-04